Latest Breaking News On - Company trappsol - Page 2 : comparemela.com

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Ongoing pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 FDA feedback provides direction for the comparative interim analysis With aligned.

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

GAINESVILLE, Fla. (BUSINESS WIRE) Nov 21, 2023

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million .

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Live webcast presentation on Thursday, October 12th at 12:00 PM ET .